A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 79-87

  O'Connor, R ^a   O'Leary, M ^b   Ballot, J ^b   Collins, C D ^b   Kinsella, P ^a   Mager, D E ^c   Arnold, R D ^c   O'Driscoll, L ^a   Larkin, A ^a   Kennedy, S ^b   Fennelly, D ^b   Clynes, M ^a   Crown, J ^b  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Clinical trial; Epirubicin; MDR; MRP 1; Phase I; Resistance modulation; Sulindac

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; CREATININE; CYCLOSPORIN; DEXAMETHASONE; EPIRUBICIN; GENTAMICIN; GLYCOPROTEIN P; GRANISETRON; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TROPONIN I; VERAPAMIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HUMAN TISSUE; INFECTION; INTESTINE CANCER; INTESTINE OBSTRUCTION; KIDNEY CANCER; KIDNEY DISEASE; LIVER TOXICITY; LUNG CANCER; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIDRUG RESISTANCE; NAUSEA; OPEN STUDY; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCARDIUM; NEOPLASMS; P-GLYCOPROTEIN; PLATELET COUNT; PROSPECTIVE STUDIES; SULINDAC; TROPONIN;

EID: 33751263449     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0240-7     Document Type: Article

References (33)

1. Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229
2. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162
3. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73
4. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodys-plastic syndrome: a phase III trial (E2995). J Clin Oncol 22:1078-1086
5. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R (1998) Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4:1451-1457
6. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165
7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
8. Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237
9. Rappa G, Finch RA, Sartorelli AC, Lorico A (1999) New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem Pharmacol 58:557-562
10. Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M (2004) Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 112:286-294
11. Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23:1161-1168
12. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9:827-836
13. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34:1250-1259
14. Stride BD, Cole SP, Deeley RG (1999) Localization of a substrate specificity domain in the multidrug resistance protein. J Biol Chem 274:22877-22883
15. Roller A, Bahr OR, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M (1999) Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 259:600-605
16. Davies NM, Watson MS (1997) Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 32:437-459
17. O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M (2004) Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457-464
18. Jones SF, Kuhn JG, Greco FA, Raefsky EL, Hainsworth JD, Dickson NR, Thompson DS, Willcutt NT, White MB, Burris HA III (2005) A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Clin Lung Cancer 6:361-366
19. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN (2003) Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21:3454-3461
20. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237-2243
21. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J, Ferrans VJ (2001) The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48:297-304
22. Grgurinovich N (1987) High-performance liquid-chromatography of sulindac and its sulfone and sulfide metabolites in plasma. J Chromatogr Biomed Appl 414:211-216
23. Swanson BN, Boppana VK (1981) Measurement of sulindac and its metabolites in human-plasma and urine by high-performance liquid-chromatography. J Chromatogr 225:123-130
24. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
25. Gabrielsson J, Weiner D (1997) Pharmacokinetic/pharmacodynamic data analysis concepts and applications. Stockholm Apotekarsocieteten, Stockholm
26. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (Abc) in immunoperoxidase techniques - a comparison between Abc and unlabeled antibody (Pap) procedures. J Histochem Cytochem 29:577-580
27. Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3:1652-1659
28. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T (2002) Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 243:83-96
29. Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26:428-438
30. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29:391-395
31. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ (1997) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57:2452-2459
32. Burke CA, Bauer WM, Lashner B (2003) Chemoprevention of colorectal cancer: slow, steady progress. Cleve Clin J Med 70:346-350
33. Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J, Xu JY (2001) Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol 7:796-800